T1	p 110 121	subfraction
T2	p 130 191	in patients with mixed dyslipidaemia and metabolic syndrome .
T3	p 601 645	patients with mixed dyslipidaemia and MetS .
T4	p 668 841	randomised patients with low-density lipoprotein cholesterol ( LDL-C ) > 160 and TG > 200 mg/dl to rosuvastatin monotherapy 40 mg/day ( R group , n = 30 ) or rosuvastatin 10
T5	p 899 900	n
T6	i 16 43	rosuvastatin monotherapy or
T7	i 47 94	combination with fenofibrate or ?-3 fatty acids
T8	i 468 492	rosuvastatin monotherapy
T9	i 514 558	combined with fenofibrate or ?-3 fatty acids
T10	i 705 716	lipoprotein
T11	i 767 791	rosuvastatin monotherapy
T12	i 826 900	rosuvastatin 10 mg/day combined with fenofibrate 200 mg/day ( RF group , n
T13	i 903 939	30 ) or ?-3 fatty acids 2 g/day ( R?
T14	i 1048 1050	RF
T15	i 1182 1222	polyacrylamide 3 % gel electrophoresis .
T16	i 1448 1450	R?
T17	o 210 230	triglycerides ( TG )
T18	o 243 296	high-density lipoprotein cholesterol ( HDL-C ) levels
T19	o 717 728	cholesterol
T20	o 1132 1163	lipoprotein subfraction profile
T21	o 1235 1248	mean LDL size
T22	o 1314 1331	prominent with RF
T23	o 1388 1416	hypotriglyceridemic capacity
T24	o 1466 1493	in insulin resistance by RF
T25	o 1516 1554	RF significantly raised HDL-C levels (
T26	o 1595 1672	cholesterol of small HDL particles . The cholesterol of larger HDL subclasses
T27	o 1755 1768	LDL size ; RF
T28	o 1847 1872	HDL subfraction profile .